MiR-326 associates with biochemical markers of bone turnover in lung cancer bone metastasis

Bone

Volumn 52, Issue 1, 2013, Pages 532-539

  Valencia, Karmele ^a   Martín Fernández, Marta ^b   Zandueta, Carolina ^a   Ormazábal, Cristina ^a   Martínez Canarias, Susana ^a   Bandrés, Eva ^a,c   de la Piedra, Concepción ^b   Lecanda, Fernando ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c Universidad Pública de Navarra   (Spain)

Author keywords

BGP; Biomarker; Osteoclast; Osteolysis; PINP; Zoledronic acid

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; CARBOXY TERMINAL TELOPEPTIDE; MICRORNA; MICRORNA 326; OSTEOCALCIN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BONE LESION; BONE METASTASIS; BONE RADIOGRAPHY; BONE TURNOVER; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MODEL; FEMALE; HUMAN; HUMAN CELL; LUNG CANCER; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; OSTEOLYSIS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; RELIABILITY; RNA ANALYSIS; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR VOLUME;

BIOLOGICAL MARKERS; BONE NEOPLASMS; BONE REMODELING; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MODELS, MOLECULAR; X-RAY MICROTOMOGRAPHY;

EID: 84870390937     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.10.033     Document Type: Article

References (35)

1. DeVita V.T., Lawrence T.S., Rosenberg S.A., Bajorin D.F., Basch E.M., Brennan M.F., et al. DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology 2008, Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia. 8th ed.
2. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
3. Fry W.A., Menck H.R., Winchester D.P. The National Cancer Data Base report on lung cancer. Cancer 1996, 77:1947-1955.
4. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
5. Delea T., Langer C., McKiernan J., Liss M., Edelsberg J., Brandman J., et al. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004, 67:390-396.
6. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
7. Rosen L.S., Gordon D., Tchekmedyian S., Yanagihara R., Hirsh V., Krzakowski M., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150-3157.
8. Brown J.E., Cook R.J., Major P., Lipton A., Saad F., Smith M., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
9. Demers L.M., Costa L., Chinchilli V.M., Gaydos L., Curley E., Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995, 41:1489-1494.
10. Coleman R.E., Major P., Lipton A., Brown J.E., Lee K.A., Smith M., et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005, 23:4925-4935.
11. Body J.J., Dumon J.C., Gineyts E., Delmas P.D. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer 1997, 75:408-412.
12. Costa L., Demers L.M., Gouveia-Oliveira A., Schaller J., Costa E.B., de Moura M.C., et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002, 20:850-856.
13. Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008, 14:1271-1277.
14. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
15. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
16. Png K.J., Halberg N., Yoshida M., Tavazoie S.F. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature 2012, 481:190-194.
17. Ma L., Teruya-Feldstein J., Weinberg R.A. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449:682-688.
18. Arora S., Ranade A.R., Tran N.L., Nasser S., Sridhar S., Korn R.L., et al. MicroRNA-328 is associated with (non-small) cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration. Int J Cancer 2011, 129:2621-2631.
19. Grange C., Tapparo M., Collino F., Vitillo L., Damasco C., Deregibus M.C., et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011, 71:5346-5356.
20. Skog J., Wurdinger T., van Rijn S., Meijer D.H., Gainche L., Sena-Esteves M., et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008, 10:1470-1476.
21. Keller A., Leidinger P., Borries A., Wendschlag A., Wucherpfennig F., Scheffler M., et al. miRNAs in lung cancer - studying complex fingerprints in patient's blood cells by microarray experiments. BMC Cancer 2009, 9:353.
22. Yu L., Todd N.W., Xing L., Xie Y., Zhang H., Liu Z., et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010, 127:2870-2878.
23. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:997-1006.
24. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
25. Chen X., Hu Z., Wang W., Ba Y., Ma L., Zhang C., et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012, 130:1620-1628.
26. Boeri M., Verri C., Conte D., Roz L., Modena P., Facchinetti F., et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011, 108:3713-3718.
27. Ponomarev V., Doubrovin M., Serganova I., Vider J., Shavrin A., Beresten T., et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging 2004, 31:740-751.
28. Vicent S., Luis-Ravelo D., Anton I., Garcia-Tunon I., Borras-Cuesta F., Dotor J., et al. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res 2008, 68:2275-2285.
29. Catena R., Luis-Ravelo D., Anton I., Zandueta C., Salazar-Colocho P., Larzabal L., et al. PDGFR signaling blockade in marrow stroma impairs lung cancer bone metastasis. Cancer Res 2011, 71:164-174.
30. Valencia K., Ormazabal C., Zandueta C., Luis-Ravelo D., Anton I., Pajares M.J., et al. Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res 2012, 18:969-980.
31. Luis-Ravelo D., Anton I., Vicent S., Hernandez I., Valencia K., Zandueta C., et al. Tumor-stromal interactions of the bone microenvironment: in vitro findings and potential in vivo relevance in metastatic lung cancer models. Clin Exp Metastasis 2011, 28:779-791.
32. Du C., Liu C., Kang J., Zhao G., Ye Z., Huang S., et al. MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol 2009, 10:1252-1259.
33. Liang Z., Wu H., Xia J., Li Y., Zhang Y., Huang K., et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol 2010, 79:817-824.
34. Kefas B., Comeau L., Floyd D.H., Seleverstov O., Godlewski J., Schmittgen T., et al. diPierro CG, Li Y, Chiocca EA, Lee J, Fine H, Abounader R, Lawler S, Purow B. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci 2009, 29:15161-15168.
35. Hennessey P.T., Sanford T., Choudhary A., Mydlarz W.W., Brown D., Adai A.T., et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 2012, 7:e32307.